A new PET scan tracer, [18F]FAPI-74, for imaging several cancers and sarcoidosis
Tests the [18F]FAPI-74 PET scan tracer in adults with suspected or confirmed disease.
Plain-language title generated from the registry record
Registry title: FAPI PET Imaging - An Exploratory Study
Key facts
- Where
- Baden, Geneva, Genolier, Lucerne, and Zurich, SwitzerlandSee the 5 sites
- Phase
- Phase 1/2
Where in Switzerland
- Kantonsspital BadenBaden, SwitzerlandNo longer taking part
- Hôpitaux Universitaires de Genève (HUG)Geneva, SwitzerlandNo longer taking part
- Clinique de GenolierGenolier, SwitzerlandNo longer taking part
- Luzerner KantonsspitalLucerne, SwitzerlandNo longer taking part
- Department for Nuclear Medicine, University Hospital ZurichZurich, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Martin Huellner
- Trial code
- NCT07705074
- Record updated
- 15 July 2026
- Original description
This study is testing a new imaging tracer called [18F]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis.Read full original descriptionShow less
FAPI PET Imaging - a Multicentric Exploratory Evaluation
This study is testing a new imaging tracer called [18F]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis.
[18F]FAPI-74 attaches to a protein found on cells that are active in tumors and areas of scarring or inflammation. This may help doctors see these areas more clearly than with imaging methods used today, especially in diseases where current scans do not work well.
People who join this study will get one injection of the tracer into a vein, then have one PET/CT or PET/MR scan. This takes about 2 hours in total. Researchers will compare the results with imaging the participant already had as part of their regular care, such as other PET scans, CT, or MRI. No extra treatment is given, and no other visits are needed.
The study will take place at 5 hospitals in Switzerland and plans to include about 770 adults with a confirmed or suspected diagnosis of one of the conditions being studied. The main goal is to see how clearly the tracer shows up on the scan. Researchers will also look at whether this new scan changes how confident doctors feel about a diagnosis, or changes the patient's treatment plan.
Inclusion: Written informed consent obtained and documented by the participant's signature; Age ≥18 years at the time of consent; Clinically established or suspected diagnosis or recurrence of an oncologic or non-oncologic disease as defined in chapter 7.1 of study protocol; Availability of standard-of-care imaging (e.g., clinically established PET tracer or anatomical imaging such as CT/MRI) to allow comparative evaluation.
Exclusion: Current pregnancy or breastfeeding; no pregnancy test is required for women who are postmenopausal for ≥12 months or have undergone surgical sterilization, bilateral oophorectomy, or hysterectomy; Previous hypersensitivity reactions to radiotracer administration; Participants scheduled for PET/MR imaging: Presence of MRI-incompatible metallic implants, electronic devices (e.g. pacemakers, cochlear implants), or other ferromagnetic foreign bodies; Severe claustrophobia that would preclude PET imaging; Inability to remain still for the duration of the PET/MR examination; Inability to understand the study information, for example due to language barriers; Subjects incapable of judgment (e.g. individuals under legal or medical incapacity).